Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral total knee arthroplasty~Exclusion Criteria:~* Subjects with risks of hemorrhage~* Subjects with thromboembolic risks~* Subjects who weigh less than 40 kg~* Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- DU-176b (Type: EXPERIMENTAL): DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
- enoxaparin sodium (Type: ACTIVE_COMPARATOR): enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).